title: Photodynamic Therapy for Pseudophakic Eyes Compared to Eyes With Cataract.
abstract: Verteporfin photodynamic therapy (vPDT) plays a role in the treatment of chorioretinal conditions. The purpose of this study was to compare vPDT outcomes between cataractous and pseudophakic eyes.
  
  
  
  In this prospective study of consecutive patients with choroidal neovascularization (CNV) secondary to neovascular age-related macular degeneration (nAMD) treated with vPDT, cataract and pseudophakic eyes were compared for number and timing of vPDT treatments, duration of follow-up, angiographic features, and changes in best-corrected visual acuity (BCVA).
  
  
  
  Overall, 103 eyes (n = 95) were included in the final analysis; 44 eyes in the cataract group and 59 eyes in the pseudophakic group. No significant difference in change in BCVA (P = .19) or leakage-free CNV lesions (P = .58) was found between the groups.
  
  
  
  In this study of vPDT for nAMD, there was no significant difference between eyes with cataract and pseudophakic eyes. It seems that cataract does not clinically alter the effect of vPDT. [Ophthalmic Surg Lasers Imaging Retina. 2016;47:1132-1136.].
authors.forename: Karin
authors.initials: K
authors.lastname: Mimouni
authors.forename: Michael
authors.initials: M
authors.lastname: Mimouni
authors.forename: Ido
authors.initials: I
authors.lastname: Eldar
authors.forename: Ruth
authors.initials: R
authors.lastname: Axer-Siegel
authors.forename: Michal
authors.initials: M
authors.lastname: Kramer
authors.forename: Ludmila
authors.initials: L
authors.lastname: Shani
authors.forename: Dov
authors.initials: D
authors.lastname: Weinberger
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002386:Cataract / Q000150:complications* / Q000175:diagnosis / Q000503:physiopathology; D020256:Choroidal Neovascularization / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D005260:Female; D005451:Fluorescein Angiography; D005500:Follow-Up Studies; D005654:Fundus Oculi; D006801:Humans; D008297:Male; D008875:Middle Aged; D010778:Photochemotherapy / Q000379:methods*; D017319:Photosensitizing Agents / Q000627:therapeutic use; D011166:Porphyrins / Q000627:therapeutic use*; D011446:Prospective Studies; D019591:Pseudophakia / Q000150:complications* / Q000175:diagnosis / Q000503:physiopathology; D013997:Time Factors; D016896:Treatment Outcome; D000077362:Verteporfin; D014792:Visual Acuity; D057135:Wet Macular Degeneration / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*
chemical_list: D017319:Photosensitizing Agents; D011166:Porphyrins; D000077362:Verteporfin